WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS
The shareholders approved the setting of the number of directors of Willow at 5 directors, and the following nominees were elected as directors of Willow for the ensuing year with the specific voting results being as follows:
|
Votes For |
Votes Withheld |
||
Director |
# |
% |
# |
% |
|
19,248,325 |
77.19 % |
5,686,936 |
22.81 % |
|
24,905,181 |
99.88 % |
30,080 |
0.12 % |
|
21,273,181 |
85.31 % |
3,662,080 |
14.69 % |
Dr. |
24,905,317 |
99.88 % |
29,944 |
0.12 % |
Dr. |
24,905,182 |
99.88 % |
30,079 |
0.12 % |
In addition, shareholders approved the appointment of
About
Willow develops biobased processes to manufacture ingredients for the pharmaceutical, food and beverage and consumer markets. Willow's FutureGrownTM and BioOxiTM platforms enable large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.
FutureGrown™ and BioOxi™ are registered trademarks of
For more information, visit www.willowbio.com
SOURCE